Windham Venture Partners

TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.

Clever Care Health Plan, Inc. is a healthcare company that specializes in providing Medicare Advantage plans with a focus on integrating Eastern and Western medicine. Founded in 2018 and headquartered in Westminster, California, with an additional office in Arcadia, the company offers culturally sensitive healthcare solutions designed to meet the diverse needs of its members. Clever Care connects Medicare beneficiaries to a network of healthcare providers, including hospitals and multilingual doctors, ensuring that members receive care in a language they understand. The company emphasizes preventive treatments and offers a range of services, including acupuncture, herbal remedies, and exercises like tai chi and qi gong, as well as traditional treatments such as cupping and moxibustion, aiming to enhance both the physical and mental health of its members.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.

SubjectWell is a clinical trial marketplace focused on patient recruitment, providing a risk-free platform for healthcare clients to efficiently find and screen qualified participants for clinical trials. By streamlining the recruitment process, SubjectWell helps accelerate the completion of studies, ensuring that healthcare organizations can meet their research timelines effectively. The company specializes in delivering highly qualified referrals, thereby enhancing the overall efficiency of clinical trials and contributing to advancements in medical research.

Valera Health, founded in 2015, operates a behavioral healthcare platform that integrates digital technology and data science with personalized clinical services. The company focuses on delivering comprehensive mental health care to individuals experiencing a range of conditions, from mild issues like depression to more severe disorders such as schizophrenia. By combining therapy and medication with advanced technology, Valera Health aims to provide efficient access to mental health services, particularly for hard-to-reach populations. This approach not only enhances patient outcomes but also facilitates continuous connectivity between patients and their care teams, thereby redefining the standards of high-performing mental healthcare.

Vergent Bioscience, Inc. is a company focused on improving cancer surgery outcomes through the development of molecularly-targeted imaging probes. Founded in 2013 and based in Minneapolis, Minnesota, Vergent manufactures a tumor-targeted fluorescent probe, known as VGT-309, which binds to enzymes overexpressed in various cancerous tissues. Upon injection prior to surgery, this probe activates a bright fluorescing dye that illuminates cancerous cells, allowing surgeons to differentiate between malignant and normal tissue with enhanced clarity. By providing a clear visual guide during surgical procedures, Vergent's technology aims to facilitate the complete removal of tumors and reduce the likelihood of residual cancer, thereby addressing a critical need in the surgical oncology field. The company's innovative approach is applicable to multiple cancer types, including lung, breast, ovarian, colorectal, and brain cancers, and is designed to support advanced visualization in various surgical techniques, including open, laparoscopic, and robotic surgeries.

Upward Health Inc., established in 2017 and headquartered in Providence, Rhode Island, is a specialty care coordination organization that partners with health plans and providers to deliver home-based medical and behavioral care for individuals with complex needs, such as mental illness and substance abuse disorders. The company coordinates care among members' caregivers, primary care physicians, and other specialists to facilitate recovery and safe community reintegration. By focusing on high-risk patients, Upward Health aims to improve outcomes and reduce healthcare costs for its partners.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

Valera Health, founded in 2015, operates a behavioral healthcare platform that integrates digital technology and data science with personalized clinical services. The company focuses on delivering comprehensive mental health care to individuals experiencing a range of conditions, from mild issues like depression to more severe disorders such as schizophrenia. By combining therapy and medication with advanced technology, Valera Health aims to provide efficient access to mental health services, particularly for hard-to-reach populations. This approach not only enhances patient outcomes but also facilitates continuous connectivity between patients and their care teams, thereby redefining the standards of high-performing mental healthcare.

Clever Care Health Plan, Inc. is a healthcare company that specializes in providing Medicare Advantage plans with a focus on integrating Eastern and Western medicine. Founded in 2018 and headquartered in Westminster, California, with an additional office in Arcadia, the company offers culturally sensitive healthcare solutions designed to meet the diverse needs of its members. Clever Care connects Medicare beneficiaries to a network of healthcare providers, including hospitals and multilingual doctors, ensuring that members receive care in a language they understand. The company emphasizes preventive treatments and offers a range of services, including acupuncture, herbal remedies, and exercises like tai chi and qi gong, as well as traditional treatments such as cupping and moxibustion, aiming to enhance both the physical and mental health of its members.

NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.

Upward Health Inc., established in 2017 and headquartered in Providence, Rhode Island, is a specialty care coordination organization that partners with health plans and providers to deliver home-based medical and behavioral care for individuals with complex needs, such as mental illness and substance abuse disorders. The company coordinates care among members' caregivers, primary care physicians, and other specialists to facilitate recovery and safe community reintegration. By focusing on high-risk patients, Upward Health aims to improve outcomes and reduce healthcare costs for its partners.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Valera Health, founded in 2015, operates a behavioral healthcare platform that integrates digital technology and data science with personalized clinical services. The company focuses on delivering comprehensive mental health care to individuals experiencing a range of conditions, from mild issues like depression to more severe disorders such as schizophrenia. By combining therapy and medication with advanced technology, Valera Health aims to provide efficient access to mental health services, particularly for hard-to-reach populations. This approach not only enhances patient outcomes but also facilitates continuous connectivity between patients and their care teams, thereby redefining the standards of high-performing mental healthcare.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.

ControlRad is a company focused on creating advanced solutions to significantly lower the lifetime risk of radiation exposure associated with fixed and mobile C-arm procedures for both patients and healthcare professionals. The company develops radiation control devices that minimize ionizing radiation exposure during fluoroscopically guided interventional procedures. ControlRad's innovative add-on solutions utilize an eye tracker and a tablet interface, allowing for enhanced workflow without compromising image quality. By effectively reducing radiation dose while maintaining optimal image clarity in the areas critical for diagnosis, ControlRad supports radiologists in delivering high-quality imaging, ensuring safety and efficacy in medical procedures.

RxWare is a software-as-a-service (SaaS) company founded in 2013 that focuses on improving the patient experience for pharmaceutical drug manufacturers. The company offers a Patient Gateway, a digital infrastructure that connects various patient services and organizations, such as ePrescribing systems, specialty pharmacies, and affordability solutions. By facilitating out-of-the-box connectivity, RxWare enables pharmaceutical brands to simplify complex patient journeys, ultimately enhancing therapy outcomes and resource utilization. Additionally, its platform includes a mobile intelligence tool designed to assist individuals with diabetes by providing information on symptoms, management, and dietary recommendations, further supporting the goal of streamlining and accelerating the patient journey.

ChromaCode Inc., established in 2012 and based in Carlsbad, California, specializes in molecular diagnostics. The company develops innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using technology licensed from Caltech. ChromaCode's core products are software, reagents, and assays that enhance the multiplexing capabilities of quantitative PCR (qPCR) instruments by fivefold. Additionally, they offer molecular assays and software for various applications such as personalized medicine and pharmaceutical research. One of their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex PCR test detecting common tick-borne pathogens in a single assay. ChromaCode's technology focuses on improving signal processing from life science instrumentation, enabling cost-effective testing of multiple targets simultaneously while integrating into existing laboratory workflows.

Science Exchange, Inc. operates an online marketplace that facilitates collaboration between researchers and scientific service providers, including academic and government laboratories. Founded in 2011 and based in Palo Alto, California, the company enables users to search for, compare, and procure scientific services from U.S. research institutions, streamlining the process of obtaining quotes, managing projects, and processing payments. The platform enhances research and development productivity by automating various collaborative tasks while ensuring data security and regulatory compliance. By matching researchers seeking to outsource experiments with qualified service providers, Science Exchange makes it easier and more affordable for scientific institutions and researchers to access outsourced research and development services, ultimately accelerating the pace of scientific discovery.

Science Exchange, Inc. operates an online marketplace that facilitates collaboration between researchers and scientific service providers, including academic and government laboratories. Founded in 2011 and based in Palo Alto, California, the company enables users to search for, compare, and procure scientific services from U.S. research institutions, streamlining the process of obtaining quotes, managing projects, and processing payments. The platform enhances research and development productivity by automating various collaborative tasks while ensuring data security and regulatory compliance. By matching researchers seeking to outsource experiments with qualified service providers, Science Exchange makes it easier and more affordable for scientific institutions and researchers to access outsourced research and development services, ultimately accelerating the pace of scientific discovery.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

SubjectWell is a clinical trial marketplace focused on patient recruitment, providing a risk-free platform for healthcare clients to efficiently find and screen qualified participants for clinical trials. By streamlining the recruitment process, SubjectWell helps accelerate the completion of studies, ensuring that healthcare organizations can meet their research timelines effectively. The company specializes in delivering highly qualified referrals, thereby enhancing the overall efficiency of clinical trials and contributing to advancements in medical research.

Andros is an NCQA certified credentialing and provider data management solution that integrates software and services to enhance efficiency in the healthcare sector. The company provides its clients with significant improvements in credentialing processes, boasting a tenfold reduction in turnaround times and a fifteenfold increase in overall efficiency compared to industry norms. Andros aims to assist payers and provider organizations in mitigating compliance risks, streamlining operations, and enhancing the management of their provider networks, ultimately contributing to more effective healthcare delivery.

CVRx, Inc. is a medical device company headquartered in Minneapolis, Minnesota, that specializes in the development of implantable technologies for the treatment of high blood pressure and heart failure. Founded in 2000, the company has created Barostim NEO, a neuro-modulation therapy that activates the body's natural mechanisms to regulate blood pressure and address heart failure progression. This therapy utilizes an implantable system that is tailored to the individual needs of patients. CVRx also offers the Rheos platform, which includes an implantable pulse generator and carotid sinus leads designed to deliver therapeutic energy to the carotid arteries. With a focus on minimally invasive solutions, CVRx primarily serves patients and healthcare professionals in the United States and internationally, including markets in the United Kingdom, the Netherlands, Italy, and Germany.

NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

Nuvaira, Inc. is a medical device company based in Minneapolis, Minnesota, focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). Founded in 2008, Nuvaira specializes in a novel catheter-based Lung Denervation System that aims to address airway nerve hyperactivity by targeting the parasympathetic innervation of the lungs. This minimally invasive procedure is designed to improve lung function, enhance exercise capacity, and elevate the quality of life for patients suffering from chronic respiratory conditions. With a commitment to advancing treatment options, Nuvaira seeks to reduce the clinical consequences associated with neural hyperactivity in conditions such as COPD and asthma.

EarLens is a privately held medical technology company focused on enhancing the hearing experience for individuals with hearing loss. The firm has pioneered the Earlens Contact Hearing Solution, a groundbreaking device that directly activates the natural hearing process. This innovative system utilizes low-frequency radio signals and a small lens placed on the eardrum to vibrate it, allowing for superior sound quality and a broader bandwidth than traditional hearing aids. Unlike conventional devices that amplify sound, the Earlens solution delivers sound directly to the eardrum, thereby minimizing feedback and ensuring clear hearing in various environments. The second generation of this technology received FDA clearance in 2019, marking a significant advancement in the standard of care for hearing performance.

Nebula Genomics is a biotechnology company founded in 2016 and based in San Francisco, California. It specializes in human genome sequencing and the creation of a marketplace for genomic and health data aimed at consumers, researchers, and the medical community. The company's mission is to facilitate genomic sequencing and enhance personalized medicine by aggregating a substantial repository of genetic information. Utilizing blockchain technology, Nebula Genomics ensures that consumers retain control over their data and receive compensation for its use. The marketplace enables researchers to analyze rich genetic datasets, which can accelerate drug development and improve the efficiency of clinical trials. Founded by prominent genomics researcher George Church and his associates, Nebula Genomics offers advanced DNA sequencing technology that allows clients to explore all genes and genetic variants in the genome, thereby providing comprehensive insights into individual health.

MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.

Cureatr Inc. is a New York-based company that specializes in mobile care coordination solutions for healthcare providers. Founded in 2011, it offers a cloud-based medication management software designed to optimize patient care, particularly focusing on post-discharge medication reconciliation. The platform combines HIPAA-secure text messaging with workflow navigation tools, facilitating communication and coordination among healthcare professionals. Cureatr's software features an inbuilt dashboard that curates and analyzes patients' medication history, enabling providers to respond to real-time events and improve their interactions with patients. By streamlining these processes, Cureatr enhances the overall quality of patient care.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

EarLens is a privately held medical technology company focused on enhancing the hearing experience for individuals with hearing loss. The firm has pioneered the Earlens Contact Hearing Solution, a groundbreaking device that directly activates the natural hearing process. This innovative system utilizes low-frequency radio signals and a small lens placed on the eardrum to vibrate it, allowing for superior sound quality and a broader bandwidth than traditional hearing aids. Unlike conventional devices that amplify sound, the Earlens solution delivers sound directly to the eardrum, thereby minimizing feedback and ensuring clear hearing in various environments. The second generation of this technology received FDA clearance in 2019, marking a significant advancement in the standard of care for hearing performance.

Cartiva, Inc. is a medical device company focused on developing innovative solutions for orthopedic surgeons and patients suffering from osteoarthritis and cartilage damage. Founded in 2011 and headquartered in Alpharetta, Georgia, Cartiva markets the Cartiva Synthetic Cartilage Implant, which is designed to mimic natural cartilage and alleviate pain by restoring the joint structure in affected areas, including the first metatarsophalangeal joint, ankle, and knee. Additionally, Cartiva offers the ProxiFuse Hammertoe Correction System for the fixation of osteotomies and reconstruction of lesser toes. The company sells its products through various distributors in regions such as Brazil, Canada, and the United Kingdom. With a management team and board composed of experts in orthopedics, Cartiva aims to enhance patient outcomes through effective treatments for cartilage injuries and related discomfort. As of October 2018, Cartiva operates as a subsidiary of a larger medical group.

NeoTract, Inc. is a medical device company specializing in the development and manufacture of minimally invasive surgical devices for urological disorders. Founded in 2004 and headquartered in Pleasanton, California, NeoTract focuses on the UroLift system, which is designed to treat men with enlarged prostates while preserving normal sexual function. The company serves a diverse customer base across the United States, Europe, Australia, Canada, Mexico, and South Korea. As a subsidiary of Teleflex Urology Limited, NeoTract aims to address critical needs in the urology field through innovative clinical solutions.

Science Exchange, Inc. operates an online marketplace that facilitates collaboration between researchers and scientific service providers, including academic and government laboratories. Founded in 2011 and based in Palo Alto, California, the company enables users to search for, compare, and procure scientific services from U.S. research institutions, streamlining the process of obtaining quotes, managing projects, and processing payments. The platform enhances research and development productivity by automating various collaborative tasks while ensuring data security and regulatory compliance. By matching researchers seeking to outsource experiments with qualified service providers, Science Exchange makes it easier and more affordable for scientific institutions and researchers to access outsourced research and development services, ultimately accelerating the pace of scientific discovery.

DOTS Technology Corp, founded in 2013 and located in Natick, Massachusetts, operates a diagnostic platform designed to assist consumers with food allergies. The company is focused on developing a food allergen detection system that allows users to test food on the spot, providing immediate information to enhance decision-making and improve the overall quality of life for individuals affected by food allergies. By advancing point-of-care detection technology, DOTS aims to address the needs of millions of consumers and has applications in both consumer and industrial sectors.

GlySens Incorporated is a privately held company focused on creating a groundbreaking long-term continuous glucose monitoring system aimed at enhancing the lives of individuals with diabetes. Their innovative fully implanted sensor has demonstrated a lifespan of up to 18 months in preclinical testing and wirelessly connects to an external receiver, providing real-time glucose measurements and alerts for hypo- and hyperglycemic episodes. Unlike traditional monitoring systems that require frequent calibrations, the GlySens sensor is designed for infrequent calibration checks, significantly reducing the burden on users. This implantable continuous glucose monitoring system, known as the GlySens ICGM system, aims to deliver unobtrusive and reliable glucose monitoring, empowering users to manage their health more effectively and enjoy greater freedom in their daily lives. Currently, the GlySens ICGM system is in clinical evaluation, with initial human implant trials completed and plans for further trials underway.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Cureatr Inc. is a New York-based company that specializes in mobile care coordination solutions for healthcare providers. Founded in 2011, it offers a cloud-based medication management software designed to optimize patient care, particularly focusing on post-discharge medication reconciliation. The platform combines HIPAA-secure text messaging with workflow navigation tools, facilitating communication and coordination among healthcare professionals. Cureatr's software features an inbuilt dashboard that curates and analyzes patients' medication history, enabling providers to respond to real-time events and improve their interactions with patients. By streamlining these processes, Cureatr enhances the overall quality of patient care.

Coravin, Inc. is a company based in Burlington, Massachusetts, that specializes in designing and marketing innovative wine access systems. Founded in 2011, Coravin's proprietary technology allows users to pour wine by the glass without removing the cork, thereby preserving the wine's natural aging process and quality. This unique system caters to a diverse clientele, including wine enthusiasts, restaurants, wine stores, and wineries. In addition to its flagship product, the Coravin Wine Preservation Opener, the company offers a range of accessories such as wine access needles, capsules, and various replacement parts to enhance the user experience. Coravin's solutions enable customers to enjoy fine wines without the commitment of opening an entire bottle, making it a valuable tool for both casual drinkers and connoisseurs alike.

ClarVista Medical, Inc. is a California-based company focused on developing innovative products to address challenging ophthalmic conditions. Founded in 2012, it specializes in the HARMONI modular intraocular lens system, which enhances vision optimization during cataract surgery. The company emerged from Prospex Medical, a medical device incubator, and has since developed a robust portfolio of intellectual property. ClarVista Medical has successfully completed the first generation of the HARMONI system and conducted initial human clinical studies. It is currently working on the second generation of the HARMONI system, aiming to conduct larger clinical trials and secure essential regulatory approvals. The company's technology allows for the initial positioning of the lens and facilitates easy exchange of the lens optic, thereby providing healthcare practitioners with a customizable solution for cataract surgery tailored to individual patient needs.

Cartiva, Inc. is a medical device company focused on developing innovative solutions for orthopedic surgeons and patients suffering from osteoarthritis and cartilage damage. Founded in 2011 and headquartered in Alpharetta, Georgia, Cartiva markets the Cartiva Synthetic Cartilage Implant, which is designed to mimic natural cartilage and alleviate pain by restoring the joint structure in affected areas, including the first metatarsophalangeal joint, ankle, and knee. Additionally, Cartiva offers the ProxiFuse Hammertoe Correction System for the fixation of osteotomies and reconstruction of lesser toes. The company sells its products through various distributors in regions such as Brazil, Canada, and the United Kingdom. With a management team and board composed of experts in orthopedics, Cartiva aims to enhance patient outcomes through effective treatments for cartilage injuries and related discomfort. As of October 2018, Cartiva operates as a subsidiary of a larger medical group.

Nuelle is a sexual wellness and intimate care company focused on delivering groundbreaking solutions made specifically for women. It marries its experience in healthcare solutions, consumer products, and technology with a deep understanding of women’s unfulfilled needs. From inception, Nuelle has taken a holistic view of these needs and desires. They worked closely with thought leaders and experts in women’s sexual medicine and wellness including physicians, sex therapists, physical therapists, and psychologists. Together we developed insights that allow Nuelle to translate its scientific approach to understanding.

VytronUS, Inc. is a manufacturer of cardiac medical devices, specializing in solutions for treating cardiac arrhythmia. Founded in 2006 and based in Sunnyvale, California, the company develops innovative technologies that leverage ultrasound energy for both imaging and therapeutic purposes. Its devices facilitate precise, non-contact energy delivery and create high-resolution maps of cardiac anatomy, empowering physicians to address complex arrhythmias with enhanced visualization and precision. VytronUS's focus on automation and flexibility in its device offerings positions it as a key player in the cardiac medical device market.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company has created a minimally invasive intracanalicular scaffold that helps alleviate high intraocular pressure by restoring the natural drainage pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its glaucoma treatments, Ivantis plans to expand its research and development efforts to address other challenging diseases within the field of ophthalmology. The company's products are utilized in clinical trials by ophthalmology specialists across the United States.

RxWare is a software-as-a-service (SaaS) company founded in 2013 that focuses on improving the patient experience for pharmaceutical drug manufacturers. The company offers a Patient Gateway, a digital infrastructure that connects various patient services and organizations, such as ePrescribing systems, specialty pharmacies, and affordability solutions. By facilitating out-of-the-box connectivity, RxWare enables pharmaceutical brands to simplify complex patient journeys, ultimately enhancing therapy outcomes and resource utilization. Additionally, its platform includes a mobile intelligence tool designed to assist individuals with diabetes by providing information on symptoms, management, and dietary recommendations, further supporting the goal of streamlining and accelerating the patient journey.

Nuvaira, Inc. is a medical device company based in Minneapolis, Minnesota, focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). Founded in 2008, Nuvaira specializes in a novel catheter-based Lung Denervation System that aims to address airway nerve hyperactivity by targeting the parasympathetic innervation of the lungs. This minimally invasive procedure is designed to improve lung function, enhance exercise capacity, and elevate the quality of life for patients suffering from chronic respiratory conditions. With a commitment to advancing treatment options, Nuvaira seeks to reduce the clinical consequences associated with neural hyperactivity in conditions such as COPD and asthma.

NeoTract, Inc. is a medical device company specializing in the development and manufacture of minimally invasive surgical devices for urological disorders. Founded in 2004 and headquartered in Pleasanton, California, NeoTract focuses on the UroLift system, which is designed to treat men with enlarged prostates while preserving normal sexual function. The company serves a diverse customer base across the United States, Europe, Australia, Canada, Mexico, and South Korea. As a subsidiary of Teleflex Urology Limited, NeoTract aims to address critical needs in the urology field through innovative clinical solutions.

WellDoc, Inc. is a healthcare technology company focused on chronic disease management, particularly diabetes. Founded in 2005 and headquartered in Baltimore, Maryland, with additional offices in Wilmington, Delaware, and Bengaluru, India, WellDoc develops innovative solutions that integrate into existing healthcare workflows. Its flagship platform, DiabetesManager, provides personalized, real-time coaching and support for patients and healthcare providers, facilitating self-management and adherence to treatment regimens. The platform features tools for medication reminders, alerts for out-of-range metrics, and cloud-based analytics for tracking health outcomes. Additionally, WellDoc offers BlueStar, a mobile prescription therapy solution that guides patients in managing their diabetes. The company serves various stakeholders in the healthcare ecosystem, including payors, employers, pharmaceutical companies, and medical device firms, and has established strategic partnerships to enhance its offerings.

MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.

NeoTract, Inc. is a medical device company specializing in the development and manufacture of minimally invasive surgical devices for urological disorders. Founded in 2004 and headquartered in Pleasanton, California, NeoTract focuses on the UroLift system, which is designed to treat men with enlarged prostates while preserving normal sexual function. The company serves a diverse customer base across the United States, Europe, Australia, Canada, Mexico, and South Korea. As a subsidiary of Teleflex Urology Limited, NeoTract aims to address critical needs in the urology field through innovative clinical solutions.

MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.

Transactis, Inc. is a New York-based company specializing in Software-as-a-Service solutions for electronic bill presentment and payment. Established in 2001, Transactis enables businesses to transition from traditional paper-based billing to efficient digital alternatives. Its primary offerings include BillerIQ, a cloud platform for delivering electronic bills and accepting online, phone, and mobile payments, and DocumentIQ, a digital document management system for transforming and archiving documents. The company serves a diverse array of industries, including financial services, healthcare, utilities, and retail, among others. Operating solely through a network of resellers, which include financial institutions and technology companies, Transactis provides white-label SaaS solutions along with substantial sales, marketing, and technical support to empower its partners. The company adheres to rigorous regulatory standards, ensuring compliance with regulations such as HIPAA and PCI Level 1.

NeoTract, Inc. is a medical device company specializing in the development and manufacture of minimally invasive surgical devices for urological disorders. Founded in 2004 and headquartered in Pleasanton, California, NeoTract focuses on the UroLift system, which is designed to treat men with enlarged prostates while preserving normal sexual function. The company serves a diverse customer base across the United States, Europe, Australia, Canada, Mexico, and South Korea. As a subsidiary of Teleflex Urology Limited, NeoTract aims to address critical needs in the urology field through innovative clinical solutions.